EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • EPV-CoV19: HCW Vaccine
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • COVID-19 Coverage
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • JanusMatrix Analysis
    • High Throughput Antibody Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
  • Deimmunization
  • Lab Services
    • Lab Services Overview
    • T Cell Assays
    • HLA Binding Assays
    • HLA Transgenic Mice
    • In Vitro Immunization Protocol (IVIP)
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
  • Contact Us
Select Page
FDA Webinar: Non-clinical Immunogenicity Assessment of Generic Peptide Products: Development, Validation, and Sampling

FDA Webinar: Non-clinical Immunogenicity Assessment of Generic Peptide Products: Development, Validation, and Sampling

by Riley Nolan | Jan 26, 2021 | Events, Featured, Webinars

The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. Full Agenda Here. EpiVax CEO/CSO, Annie De Groot, presented an update on...
EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19

EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19

by Danielle Medeiros | Dec 31, 2020 | Featured, News

PROVIDENCE, R.I., Dec. 31, 2020 /PRNewswire/ — EpiVax (“EpiVax”) and EpiVax Therapeutics (“EVT”) today provide an update on the advancement of their peptide-based COVID-19 vaccine, EPV-CoV-19. EPV-CoV-19, a T cell epitope-based vaccine...
EpiVax Advances “PANDA” Peptide Therapeutic Immunogenicity Screening Program

EpiVax Advances “PANDA” Peptide Therapeutic Immunogenicity Screening Program

by Danielle Medeiros | Dec 29, 2020 | Featured, News

PROVIDENCE, R.I., Dec. 29, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today provides an update on the advancement of the company’s peptide therapeutic immunogenicity assessment program. The PANDA (Peptide Abbreviated New Drug Application)...
EpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)

EpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)

by Danielle Medeiros | Dec 15, 2020 | Featured, News

PROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020...
American Association of Pharmaceutical Scientists (AAPS) – PharmSci360

American Association of Pharmaceutical Scientists (AAPS) – PharmSci360

by Danielle Medeiros | Oct 27, 2020 | Events, Featured

EpiVax is proud to have three of our Director and Senior level scientists representing our work at the 2020 AAPS PharmSci 360 Meetings. There are several opportunities to catch up with them over the next two weeks including the following rapid fire talks: Brian...
FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities

FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities

by Danielle Medeiros | Oct 22, 2020 | Featured, News

PROVIDENCE, RI, October 22, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) and CUBRC, Inc. (“CUBRC”) announced today that they have been awarded a two-year, $1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research...
« Older Entries

Recent Posts

  • FDA Webinar: Non-clinical Immunogenicity Assessment of Generic Peptide Products: Development, Validation, and Sampling
  • January Newsletter: Duality Over Division
  • EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19
  • EpiVax Advances “PANDA” Peptide Therapeutic Immunogenicity Screening Program
  • December Newsletter: 2020 Hindsight! and Paying it Forward

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Thinking Out Loud -Blog
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2021 EpiVax, Inc. – Informatics and Immunology, All rights reserved. • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562